Clinical features, diagnosis and treatment of Paget’s disease of bone in mainland China: A systematic review

• Published in: Reviews in endocrine & metabolic disorders 2020-12, Vol.21 (4), p.645-655
• Main Authors: Wang, Qin-Yi, Fu, Shan-Jiang, Ding, Na, Liu, Shu-Ying, Chen, Rong, Wen, Zhang-Xin, Fu, Sang, Sheng, Zhi-Feng, Ou, Yang-Na
• Format: Article
• Language: English
• Subjects: Diabetes; Endocrinology; Internal Medicine; Medicine; Medicine & Public Health
• ISSN: 1389-9155; 1573-2606
• DOI: 10.1007/s11154-020-09544-x

Paget’s disease of bone (PDB) is a metabolic bone disease with distinct geographical and ethnic differences in its pathogenesis. In this study, we aimed to retrospectively analyze the clinical features and the status of diagnosis and treatment of PDB in mainland China to improve the clinician’s understanding of this disease. For this purpose, we conducted a systematic review of 118 articles, including a total of 332 patients with PDB. The results showed that the onset age of PDB in mainland China was 46–60 years. The number of male patients in most age groups was slightly higher than that of female patients, but there was no statistical difference ( p  > 0.05). The gender ratio (male to female) of PDB in mainland China was significantly different from that in Japan ( p   0.05). The clinical manifestations of PDB patients in mainland China mainly included ostealgia, bone malformation, hearing loss, and fracture, and bisphosphonate was used as the main treatment drug. These findings were similar to those in Japan, UK, and USA. Total alkaline phosphatase (TALP) level was elevated in about 89.7% of patients, and no correlation between TALP level and ostealgia was observed ( p  > 0.05). In addition, no difference in TALP level between males and females in each group was observed ( p  > 0.05).